We have previously reported that mutations of EGFR, KRAS, BRAF and HER2 were mutually exclusive in 691 resected NSCLC tumors indicating that a single activating mutation in the EGFR-RAS-RAF signaling pathway may be sufficient for the pathogenesis of many lung cancers [10], [14]. Here, KRAS is linked to lung cancer.